144 related articles for article (PubMed ID: 30488730)
21. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting.
Olofsson S; Norrlid H; Karlsson E; Wilking U; Ragnarson Tennvall G
Breast; 2016 Oct; 29():140-6. PubMed ID: 27498127
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of Trastuzumab After Subcutaneous and Intravenous Administration in Obese Patients.
González García J; Gutiérrez Nicolás F; Ramos Díaz R; Nazco Casariego GJ; Viña Romero MM; Llabres Martinez M; Llanos Muñoz M; Batista López JN; Jiménez Sosa A; Ceballos Lenza I; Cruz Jurado J
Ann Pharmacother; 2020 Aug; 54(8):775-779. PubMed ID: 31971005
[No Abstract] [Full Text] [Related]
23. Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer.
Rojas L; Muñiz S; Medina L; Peña J; Acevedo F; Pinto MP; Sanchez C
PLoS One; 2020; 15(2):e0227961. PubMed ID: 32023267
[TBL] [Abstract][Full Text] [Related]
24. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.
Wynne C; Harvey V; Schwabe C; Waaka D; McIntyre C; Bittner B
J Clin Pharmacol; 2013 Feb; 53(2):192-201. PubMed ID: 23436264
[TBL] [Abstract][Full Text] [Related]
25. Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden.
Hedayati E; Fracheboud L; Srikant V; Greber D; Wallberg S; Linder Stragliotto C
PLoS One; 2019; 14(2):e0211783. PubMed ID: 30716137
[TBL] [Abstract][Full Text] [Related]
26. Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice.
Waller CF; Möbius J; Fuentes-Alburo A
Br J Cancer; 2021 Apr; 124(8):1346-1352. PubMed ID: 33589773
[TBL] [Abstract][Full Text] [Related]
27. Flexible care in breast cancer.
Wardley A; Canon JL; Elsten L; Peña Murillo C; Badovinac Crnjevic T; Fredriksson J; Piccart M
ESMO Open; 2021 Feb; 6(1):100007. PubMed ID: 33450658
[TBL] [Abstract][Full Text] [Related]
28. Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study.
Pivot X; Spano JP; Espie M; Cottu P; Jouannaud C; Pottier V; Moreau L; Extra JM; Lortholary A; Rivera P; Spaeth D; Attar-Rabia H; Benkanoun C; Dima-Martinez L; Esposito N; Gligorov J
Eur J Cancer; 2017 Sep; 82():230-236. PubMed ID: 28648618
[TBL] [Abstract][Full Text] [Related]
29. Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab.
Franken M; Kanters T; Coenen J; de Jong P; Jager A; Groot CU
Breast; 2020 Aug; 52():71-77. PubMed ID: 32447129
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
31. [Subcutaneous administration of trastuzumab at home: Feedback of patients treated in 2016 by Santé service].
Pailler C; Chapot T; Softa S; Gandrille N; Ruiz D; Mathieu S; Delaloge S
Bull Cancer; 2018 Dec; 105(12):1126-1134. PubMed ID: 30466957
[TBL] [Abstract][Full Text] [Related]
32. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A
Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146
[TBL] [Abstract][Full Text] [Related]
33. Cost-minimisation analysis of intravenous versus subcutaneous trastuzumab regimen for breast cancer management in Hong Kong.
Lee VWY; Cheng FWT
Hong Kong Med J; 2023 Feb; 29(1):16-21. PubMed ID: 36731884
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
[TBL] [Abstract][Full Text] [Related]
35. Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time-motion study with mixed-methods research.
Lin HW; Lin CY; Yeh TP; Lin TC; Yeh WC; Yang LC; Chen YC; Chiu LY; Wu CT; Chen CJ; Chen YF; Wang HC; Wu YC; Liu LC
BMJ Open; 2023 Mar; 13(3):e059288. PubMed ID: 36927581
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
[TBL] [Abstract][Full Text] [Related]
37. First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer.
Araki K; Fukada I; Yanagi H; Kobayashi K; Shibayama T; Horii R; Takahashi S; Akiyama F; Ohno S; Ito Y
Breast; 2017 Oct; 35():78-84. PubMed ID: 28662406
[TBL] [Abstract][Full Text] [Related]
38. [Trastuzumab and its biosimilars].
Sarosiek T; Morawski P
Pol Merkur Lekarski; 2018 May; 44(263):253-257. PubMed ID: 29813044
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
40. Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer.
Melichar B; Študentová H; Kalábová H; Vitásková D
Immunotherapy; 2014; 6(7):811-9. PubMed ID: 25290414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
